Filter by: Subject

Filter by: Subject

Results Per Page:

Positron emission tomography (PET) (28)
Positron emission tomography/computed tomography (PET/CT) (20)
Prostate cancer (15)
SDG-03: Good health and well-being (15)
Prostate-specific membrane antigen (PSMA) (11)
Nuclear medicine (10)
Infection (9)
Tuberculosis (TB) (9)
South Africa (SA) (8)
PET/CT (7)
Coronavirus disease 2019 (COVID-19) (6)
COVID-19 pandemic (6)
Human immunodeficiency virus (HIV) (6)
Radiopharmaceuticals (6)
Cancer (5)
Cervical cancer (5)
Molecular imaging (5)
Theranostics (5)
Antimicrobial peptide (AMP) (4)
Computed tomography (CT) (4)
Fluorodeoxyglucose positron emission tomography (FDG PET) (4)
HIV infection (4)
Prostate carcinoma (4)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (4)
[18F]FDG PET/CT (3)
Africa (3)
Bacteria (3)
Biodistribution (3)
Breast cancer (3)
Diagnosis (3)
Infection imaging (3)
Inflammation (3)
Invasive fungal infection (IFI) (3)
Patients (3)
Prostate specific membrane antigen (PSMA) (3)
Radioligand therapy (3)
Ubiquicidin (3)
177Lu-PSMA (2)
18F-FDG (2)
18F-FDG PET/CT (2)
18F-fluciclovin PET (2)
18F-fluciclovine PET/CT imaging (2)
68Ga (2)
68Ga-PSMA (2)
68Ga-PSMA PET (2)
[68Ga]Ga-NODAGAZOL (2)
Actinium-225 (2)
Angiogenesis (2)
Anti-tuberculous treatment (ATT) (2)
Arterial inflammation (2)
Biochemical recurrence (BCR) (2)
Bone scan (2)
Case report (2)
Computerized tomography (CT) (2)
Developing countries (2)
Diagnostic imaging (2)
DOTA (2)
FDG PET (2)
Fibroblast activation protein inhibitor (FAPI) (2)
Fluorodeoxyglucose (FDG) (2)
HIV/AIDS (2)
Hypoxia (2)
Immunohistochemistry (2)
In vivo (2)
Invasive fungal disease (IFD) (2)
Invasive fungal infections (2)
Magnetic resonance imaging (MRI) (2)
Medical imaging (2)
Metabolic tumor volume (MTV) (2)
Metastatic castration-resistant prostate cancer (mCRPC) (2)
Microemulsion (2)
NODAGA (2)
Patient management (2)
Peptide receptor radionuclide therapy (PRRT) (2)
PET imaging (2)
Prevention (2)
Quality control (2)
Radiochemistry (2)
Radiolabeling (2)
Radiomics (2)